Skip to content

UNITED HEALTH PRODUCTS, INC.: 10-Q filed 2025-08-14

What UNITED HEALTH PRODUCTS, INC. reported in its quarterly report filed 2025-08-14 (fiscal Q2 2025): 31 published measures, 88 facts as tagged in accession 0001477932-25-005894.

This filing

Form
10-Q (quarterly report)
Filed
2025-08-14
Fiscal period
fiscal Q2 2025
Accession
0001477932-25-005894 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All UNITED HEALTH PRODUCTS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-06-3081,538USD
At 2024-12-31269,979USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-06-303,252,090USD
At 2024-12-312,713,810USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-06-30-3,170,552USD
At 2025-03-31-2,855,365USD
At 2024-12-31-2,443,831USD
At 2024-06-30-2,002,421USD
At 2024-03-31-1,795,990USD
At 2023-12-31-1,714,226USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-315,187USD91
2025-01-01 to 2025-06-30-1,846,846USD181
2025-01-01 to 2025-03-31-1,531,659USD90
2024-04-01 to 2024-06-30-432,021USD91
2024-01-01 to 2024-06-30-883,959USD182
2024-01-01 to 2024-03-31-451,938USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-06-30-458,658USD181
2024-01-01 to 2024-06-30-693,481USD182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2025-04-01 to 2025-06-300USD91
2025-01-01 to 2025-06-300USD181
2024-04-01 to 2024-06-300USD91
2024-01-01 to 2024-06-300USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-06-30290,000USD181
2024-01-01 to 2024-06-30616,815USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-06-300USD181
2024-01-01 to 2024-06-300USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-06-30-80,547,789USD
At 2024-12-31-78,700,943USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-04-01 to 2025-06-30257,139,815shares91
2025-01-01 to 2025-06-30255,684,472shares181
2024-04-01 to 2024-06-30247,717,837shares91
2024-01-01 to 2024-06-30246,734,321shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-04-01 to 2025-06-300USD/shares91
2025-01-01 to 2025-06-300.01USD/shares181
2024-04-01 to 2024-06-300USD/shares91
2024-01-01 to 2024-06-300USD/shares182

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-06-300USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-268,356USD91
2025-01-01 to 2025-06-30-1,757,572USD181
2024-04-01 to 2024-06-30-405,177USD91
2024-01-01 to 2024-06-30-830,271USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-06-3021,111USD
At 2024-12-31191,683USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2025-04-01 to 2025-06-3025,100USD91
2025-01-01 to 2025-06-3045,812USD181
2024-04-01 to 2024-06-307,613USD91
2024-01-01 to 2024-06-3015,226USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-06-301,904,590USD
At 2024-12-311,641,152USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2025-06-3026,325USD
At 2024-12-3128,350USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-04-01 to 2025-06-30268,356USD91
2025-01-01 to 2025-06-301,757,572USD181
2024-04-01 to 2024-06-30405,177USD91
2024-01-01 to 2024-06-30830,271USD182

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2025-04-01 to 2025-06-30187,373USD91
2025-01-01 to 2025-06-301,560,338USD181
2024-04-01 to 2024-06-30339,457USD91
2024-01-01 to 2024-06-30648,999USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-04-01 to 2025-06-3080,983USD91
2025-01-01 to 2025-06-30197,234USD181
2024-04-01 to 2024-06-3065,720USD91
2024-01-01 to 2024-06-30181,272USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-06-30257,133,222shares
At 2024-12-31252,408,222shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-06-30225USD
At 2024-12-31168,883USD
At 2024-06-3018,754USD
At 2023-12-3195,420USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-06-3077,136,474USD
At 2024-12-3176,004,704USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-06-3031,252USD
At 2024-12-3147,096USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-06-3032,535USD
At 2024-12-3148,489USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2025-06-30847,500USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-06-3020,886USD
At 2024-12-3122,800USD

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2025-01-01 to 2025-06-302,025USD181
2024-01-01 to 2024-06-302,025USD182

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2025-04-01 to 2025-06-30-46,831USD91
2025-01-01 to 2025-06-30-89,274USD181
2024-04-01 to 2024-06-30-26,844USD91
2024-01-01 to 2024-06-30-53,688USD182

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-06-300USD181
2024-01-01 to 2024-06-300USD182

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2025-01-01 to 2025-06-300USD181
2024-01-01 to 2024-06-300USD182

Inspect the source

Entity
UNITED HEALTH PRODUCTS, INC. / CIK 0001096938
Captured
2026-09-20T05:22:35.874Z
SEC response SHA-256
ac6cf9d703c0adca8f17a2c8b6ab295df7496239afbd8b7d9c595d23b1e2267e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001096938.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))